Company intelligence / Profile preview

Cognizance Biomarkers

Lower Gwynedd/Spring House, Pennsylvania, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Clinical

Overview

Cognizance Biomarkers’ lead product, EvoScoreDX, is a blood-based proteomic biomarker test that demonstrated sensitivity and specificity of ≥90% in distinguishing epileptic from nonepileptic events. Clinical trials have been conducted to confirm its ability to differentiate between epileptic seizures and psychogenic nonepileptic seizures. The technology aims to provide rapid, objective diagnosis and enable better disease management for epilepsy patients.

Therapeutic areas: Neurology
Modalities: Diagnostic testProteomic-based assayGenomic-based assay
Industry: Protein Biomarker Diagnostics

Drug pipeline

2 assets

EvoScoreDX

Clinical

Indications: Epilepsy

1 more asset in the full pipeline.

Request access →

Partnerships

Mayo Clinic

Beyond the preview

Go deeper on Cognizance Biomarkers.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cognizance Biomarkers.

Explore the full profile